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Abstract
Background Pancreatic ductal adenocarcinoma (PDAC) has
a dismal prognosis with a 5-year survival rate of <5% and an
average survival of only 6 months. Although advances have
been made in understanding the pathogenesis of PDAC in
the last decades, overall survival has not changed. Various
clinicopathological and immunohistological variables have
been associated with survival time but the exact role that
these variables play in relation to survival is not clear.
Methods and results To examine how the variables affected
survival independently, multivariate analysis was conducted
inastudygroupof78pancreaticductaladenocarcinomas.The
analysis included clinicopathological parameters and protein
expression examined by immunohistochemistry of p53,
Smad4, Axl, ALDH, MSH2, MSH6, MLH1 and PMS2.
Lymph node ratio <0.2 (p00.004), tumor free resection mar-
gins (p00.044) and Smad4 expression (p00.004) were the
only independent prognostic variables in the multivariate
analysis. Expression of the other proteins examined was not
significantly related to survival.
Conclusions Discrepancieswithotherstudiesinthisregardare
likely due to differences in quantification of immunohisto-
chemicalstainingandthelackofmultivariateanalysis.Itunder-
scores the importance to standardize the methods used for the
application of immunohistochemistry in prognostic studies.
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Abbreviations
PDAC pancreatic ductal adenocarcinoma
MMR miss-match repair
ALDH aldehyde dehydrogenase
TMAs tissue micro arrays
IHC Immunohistochemistry
LNR lymph node ratio
OS overall survival
1 Introduction
Pancreatic ductaladenocarcinoma(PDAC) has a dismalprog-
nosis with an annual mortality rate almost equaling incidence.
Approximately 36.800 patients die annually from PDAC in
the USA, making it the fourth leading cause of cancer-related
death [1]. Five-year survival rates have not changed over the
last decades and are currently still <5% [2–4]. Although
advances have been made in the understanding of the patho-
genesis of PDAC, these were not translated into improved
prognosis [5]. Most patients present with locally advanced or
distant metastatic disease, making resection with curative
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for resection only 10–18% will reach 5-year survival. Still,
5-yearsurvivalcannotbeequated tocurebecause patientsstill
die from recurrent disease after 5 years [6, 7].
Clinicopathological factors such as low disease stage [4,
8], resection margin [4, 8] and lymph node metastasis [9]
have been associated with survival although the exact role
of these characteristics in survival is unknown. Moreover,
various tumor-specific protein expression patterns have
been reported to be associated with overall survival in
pancreatic cancer patients. Persistent expression of Smad4,
a tumor suppressor gene affected in ~55% of PDACs, was
found to be a strong prognosticator improving both disease-
free and overall survival (OS) [10, 11]. Furthermore,
micro-satellite instability, caused by defects in the mis-
match repair (MMR) genes, has been reported to affect
prognosis favorably [12] although not all studies confirm
this [13, 14]. Another protein described to be associated
with prognosis in PDAC is Axl, a receptor tyrosine kinase
often involved in cancer development [15, 16]. Recently, a
study by Rasheed et al. linked expression of aldehyde
dehydrogenase (ALDH) to worse prognosis; it was sug-
gested that ALDH-positive cells have tumor-initiating po-
tential and that the percentage of ALDH-positive cells
negatively affects OS [17]. However, in most of these
studies, the clinical and histological characteristics were
evaluated without adjustment for other variables that affect
prognosis through a multivariate analysis.
To examine whether the different clinical and histological
factors affect survival independently, a multivariate analysis
was therefore conducted on a cohort consisting of 78
PDACs. The variables included clinicopathological parame-
ters and expression patterns of most of the proteins previously
reported to have a role in PDAC survival. The following
proteins were examined: p53, Smad4, Axl, ALDH, and four
mismatch repair genes; MSH2, MSH6, MLH1 and PMS2.
2 Methods
2.1 Patient selection
Paraffin-embeddedtissuefrom78primary infiltratingPDACs
wasobtainedfromtheSurgicalPathologyarchivesof3cancer
treatment centers: the University Medical Center Utrecht, the
Academic Medical Center Amsterdam and the Erasmus
Medical Center Rotterdam. Clinical data that was obtained
included age, sex, tumor size, TNM-stage, histological grade,
lymph-node status and exact survival time in months for all
patients. Data were not available with respect to treatment of
the patients or time of recurrence of the tumors and could
therefore not be linked with the parameters investigated
in this study.
2.2 Tissue micro arrays (TMAs)
TMAs were developed using formalin fixed paraffin embed-
ded tissue as previously described [8, 18]. Briefly, for each
case representative areas containing neoplastic cells were
marked on a hematoxylin-eosin stained sections which
served as template. Three 0.6 mm cores were punched from
the donor block and injected into the receiver block. For
each patient, a 0.6 mm core from a non-neoplastic lymph
node was included as control tissue.
2.3 Immunohistochemistry (IHC)
IHC was performed on 4 μm-thick sections of the TMAs to
analyse expression of p53, Smad4, Axl, ALDH and the four
MMR proteins MSH2, MSH6, MLH1 and PMS2. Sections
were deparafinized using routine techniques. Endogenous
peroxidase activity was blocked with 3% H2O2 in methanol
for 10 min after which sections were pretreated if necessary
with ARS pH 9 for 10 min in the autoclave and cooled for
10 min. Before primary antibody application, sections were
incubated with Protein Block Serum-Free (Dako Cytoma-
tion, Carpenteria, CA, USA). Then primary antibodies
were applied. Antibody binding was visualized using the
PowerVision+Poly-HRP kit (Immunologic, Duiven, The
Netherlands) with 3,3-diaminobenzidin (DAB; Sigma-
Aldrich, Seelze, Germany) or DAB+(Dako Cytomation) as
chromogen. Sections were counterstained with hematoxylin
and cover slips were applied. The primary antibodies that
were used, their dilution and incubation time are described
in Table 1.
IHC labeling was scored by a single investigator after
consensus was reached about cut off levels with an experi-
enced pathologist behind a multiheaded microscope. In case
of doubt, sections were again evaluated with the pathologist.
Scoring was then based on consensus after discussion. The
scoring method differed per antibody. P53 staining was
scored as positive when nuclear accumulation of the protein
was observed in more than 80% of the cancer cells. Absent
or diffuse weak staining was scored as negative, indicating
normal expression of p53. Smad4 and the MMR proteins
were scored as negative when labeling was absent in the
neoplastic cells. Weak or strong labeling was scored as
positive. Axl staining was scored as negative when labeling
was observed in 0–10% of the neoplastic cells. Slides show-
ing labeling in >10% of the neoplastic cells were scored as
positive. Scoring methods used in this study correspond
with previously published papers [15, 19, 20]. For ALDH,
scoring was performed in two different ways. First, sections
were scored in a similar way as was described for Axl. The
second way to score ALDH staining was according to the
method reported by Rasheed et al. [17]. Only tumors exhibit-
ing intense staininginbothnucleiand cytoplasm ofneoplastic
120 N.A. Ottenhof et al.cells, that was at least 2-fold higher than staining in normal
pancreatic acinar cells adjacent to the tumor, were scored as
positive (Figure 1). In most cases the 3 tissue cores showed
similar staining intensity. In some cases, staining intensity
differed between the cores. However, scoring was performed
per tumor, not per core. Therefore, the 3 cores were evaluated
asawholeandtheIHCscorewasbasedonthetotalcancercell
population in the 3 cores.
2.4 Statistical analysis
Statistical analysis was performed using SPSS version 15.0
(SPSS, Chicago, IL, USA). Associations between the dif-
ferent variables were examined using the Pearson’sC h i
Square test. The survival was estimated by the Kaplan-
Meier method and tested by log-rank test for statistical
significance. Kaplan-Meier graphs were plotted using
GraphPad Prism (GraphPad, La Jolla, CA USA). To evalu-
ate correlations between the different variables, a Pearson’s
correlation coefficient was calculated for both clinical char-
acteristics and protein expression patterns. The variables
with prognostic potential in the univariate analyses (p≤0.10)
and the variables that correlated significantly with one of the
parameters were included in the multivariate analysis.
Variablesthatdidnotcorrelatesignificantlywereremovedina
step-wise manner. The Cox proportional hazards model was
used. A p-value <0.05 was considered to indicate statistical
significance.
3 Results
3.1 Clinical characteristics
The mean age of the 78 patients was 63 (range, 40–77). The
diagnosis PDAC was confirmed in all patients. The median
overall survival was 27 months. Twelve patients (15%)
reached 5-year survival, 2 patients (3%) reached 10-year
survival. Three patients presented with PDAC in the tail of
the pancreas. The other 75 were diagnosed with a tumor in
the head of the pancreas. Sixty-nine patients underwent a
Whipple’s pancreatoduodenectomy. Seven other patients
Table 1 Antibodies used for immunohistochemistry
Antibody Company Pretreatment/Dilution Incubation time Substrate
p53 (BP53-12) Cat. #MS-738-7 Thermo Scientific, Fremont, CA, USA ARS pH9/1:2000 1 h, room temperature DAB
Smad4 (B-8) Cat. #sc-7966 Santa Cruz Biotechnology, Santa Cruz,
CA, USA
ARS pH9/1:300 1 h, room temperature DAB+
ALDH Cat. #61195 BD Transduction Laboratories, Franklin
Lakes, NJ, USA
ARS pH9/1:200 1 h, room temperature DAB
Axl Cat #AF154 R&D Systems, Minneapolis, MN, USA None/1:100 1 h, room temperature DAB
MLH1 Cat. #13271A BD Pharmingen, San Diego, CA, USA ARS pH9/1:50 Overnight, 4 C DAB+
MSH2 Cat. # NA27 Oncogene Research Products, Schwalbach,
Germany
ARS pH9/1:200 Overnight, 4 C DAB+
MSH6 Cat. # 610919 BD Transduction Laboratories ARS pH9/1:200 Overnight, 4 C DAB+
PMS2 Cat. #556415 BD Transduction Laboratories ARS pH9/1:500 Overnight, 4 C DAB+
Fig. 1 Immunohistochemical evaluation of both negative (a,c,e,g) and
positive (b,d,f,h) expression of ALDH (a/b), Axl (c/d), Smad4 (e/f)
and p53 (g/h). Arrows intense staining of ALDH in the basally located
neoplastic cells
Prognostic Significance of Protein Expression in PDAC 121underwent either a pylorus-preserving pancreatoduodenec-
tomy (n06) or a complete pancreatoduodenectomy (n01).
Two patients underwent corpus/tail resection. Operation
procedures did not affect survival (p00.48). Demographics
and tumor characteristics are listed in Table 2. Univariate
analysis revealed no differences in survival time related to
age, gender, tumor size or histological grade. Absence of
lymph node metastasis and a tumor-free resection margin
showed a borderline significant correlation with improved
survival (p00.07 and p00.06, respectively). The variables
significantly improving survival as was shown by univariate
analysis were lymph node ratio (LNR) (OS LNR<0.2,
34.5 months; LNR>0.2, 15.6 months; p00.002) and tumor
stage (OS stage I or IIA, 43.1 months; stage IIB or III,
21.0 months; p00.02) (Figure 2).
3.2 Immunohistochemical evaluation
We determined protein expression by immunohistochemis-
try for 8 different proteins. Strong nuclear staining of p53,
indicating a defect in the protein, was found in 54% of the
cases. Smad4 expression was completely absent in 43% of
the cases. Staining of the mismatch repair proteins MSH-2,
MSH-6, PMS-2 and MLH-1 was unaffected in 95%, 97%,
93% and 99%, of the cases, respectively. Axl expression
was observed in 22% of the tumors. The other tumors were
Axl negative. Although 75% of the tumors exhibited posi-
tive staining of ALDH protein, high intensity staining of
ALDH protein as described by Rasheed et al.(17) was
observed in only 11 tumors (16%).
Univariate analysis revealed Smad4 expression as a
strong prognostic variable for survival (p00.008) (Table 3).
The other variables did not have a statistically significant
prognostic value.
3.3 Multivariate analysis
To evaluate the correlation between the different variables,
Pearson’s correlation coefficient was calculated for both the
clinical characteristics and protein expression patterns.
Table 2 Distribution of
demographic and tumor-related
factors and univariate
survival analysis for
78 PDAC patients
a Significant correlation with
survival
Total (n078) Median survival
(months)
95% CI p value
(log-rank test)
Demographics
Age (%) 0.69
< 65 years 39 (50%) 24.8 13.9–35.8
≥ 65 years 39 (50%) 28.5 27.5–39.4
Gender 0.76
male 35 (45%) 23.6 15.6–31.5
female 43 (55%) 29.2 16.8–41.6
Tumor characteristics
Tumor size (cm) (1 case missing) 0.23
<2,0 13 (17%) 43.8 9.0–78.6
≥2,0 64 (83%) 22.7 16.7–28.7
Histological grade (1 case missing) 0.81
poor 21 (27%) 23.8 8.5–39.1
moderate 40 (52%) 27.9 16.2–39.7
well 16 (21%) 28.7 15.7–41.7
Stage 0.02
a
I or/IIA 20 (26%) 43.1 24.2–62.1
IIB or III 58 (74%) 21.0 13.4–28.6
Lymph node status (1 case missing) 0.07
N0 23 (43%) 38.7 21–56
N1 54 (57%) 16.8 14–30
Lymph node ratio (1 case missing) 0.002
a
<0.2 46 (60%) 34.5 22.6–46.4
≥0.2 31 (40%) 15.6 9.2–22.1
Resection margin 0.06
R0 52 (67%) 31.6 22.6–46.4
R1 26 (33%) 15.6 9.2–22.1
122 N.A. Ottenhof et al.Tumor stage was significantly correlated with lymph node
ratio (p<0.001) and resection margin (p00.04). There was a
strong correlation between expression of MMR proteins.
MSH2 and MSH6 expression were strongly correlated (p0
0.005), as were PMS2 and MLH1 expression (p<0.001).
The variables that had prognostic potential in the univar-
iate analysis (p≤0.10) or that were significantly correlated
with one of the variables were subjected to multivariate
analysis. The analysis included the variables lymph node
status, LNR, resection margin, tumor stage and Smad4
expression. LNR <0.2, a tumor-free resection margin and
persistent Smad4 expression significantly favored survival
in multivariate analysis as shown in Table 4.
4 Discussion
Although tremendous progress has been made over the last
decades in the understanding of the pathogenesis of PDAC,
PDAC patients still die within a few months after diagnosis.
Critical analysis of factors involved in survival and progno-
sis potentially leads to a better understanding of the patho-
genesis of PDAC. Therefore, identification of patient- and/
or tumor-specific characteristics associated with increased
survival time is an important strategy. Although multiple
studies have been conducted concerning the prognostic sig-
nificance of different variables, the picture remains incom-
plete and unclear. Tumor size, lymph node involvement,
resection margin and histological grade have all been
reported to significantly affect survival time (4, 8), although
inconsistencies between studies remain [6, 21]. At present,
only LNR was found to be a significant prognosticator in
every study it was evaluated in [6, 9, 21, 22].
Apart from the different demographics, immunohisto-
chemical evaluation of protein expression revealed multiple
potential prognosticators in PDAC in recent publications
[11, 15, 21–23]. However, multivariate analysis to evaluate
whether these proteins have independent prognostic
Fig. 2 Kaplan-meier plots
of overall survival of 78 PDAC
patients in relation to node
status (log-rank p00.066),
resection margin (log-rank
p00.056), lymph node ratio
(log-rank p00.002), Smad4
expression (log-rank p00.008)
and tumor Stage (log-rank
p00.02)
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evaluate results from earlier publications on the prognostic
relevance of clinical characteristics and to determine the role
thatvariousproteinsplayinprolongedsurvival,weperformed
multivariate analysis including most characteristics that have
been implicated to be involved. Most importantly, we tried to
identify which proteins remained significant for prognosis in
multivariate analysis.
In the current study, LNR <0.2 was the strongest prognos-
ticator which confirms results from other studies [23–25].
Another important prognostic factor that was described pre-
viously, persistent Smad4 expression [10, 11], was also a
significantly favorable prognosticator with respect to survival
in our cohort and remained so in multivariate analysis.
Positive Axl expression in PDAC has been related to
shorter overall survival [15, 16]. Unfortunately, multivariate
analysis was not performed by Koorstra et al. [15]. Song et al.
[16] performed multivariate analysis including both Axl ex-
pression and lymph node involvement which resulted in a
marginally significant effect of Axl on survival time. Howev-
er, this study included only stage II PDACs making compar-
ison with our results difficult. We did not detect a correlation
between either Axl expression and lymph node status or Axl
expression and survival time. Furthermore, only 23% of the
tumors expressed Axl, which is a much lower proportion than
described previously. It is possible that the scoring method for
Axl expression in our study differed, leading to a smaller
percentage of Axl-positive tumors. Because of these contra-
dictory findings on Axl expression in PDAC, conclusions on
the prognostic relevance of Axl expression cannot be drawn
and it seems advisable to further delineate the role of Axl in
PDAC development and progression.
Anothergroupofproteinsreportedtoaffectsurvivalarethe
MMR proteins MSH2, MSH6, MLH1 and PMS2. Mutations
or epigenetic changes in these genes lead to microsatellite
instability. Microsatellite instable tumors have been claimed
to have a significantly better prognosis than their microsatel-
lite stable counterparts [12, 13]. Although we did not assess
microsatellite instability, we evaluated MMR protein activity
usingIHC.Similartopreviouslypublisheddata,approximate-
ly 13% of the tumors showed absence of expression of one or
more of the MMR proteins [12, 26]. There was a strong
correlation between the expression of the different mismatch
repair proteins. MSH2 and MSH6 expression were strongly
correlated, as were MLH1 and PMS2 expression. This was
expected as both MSH2/MSH6 and MLH1/PMS2 form het-
erodimers through which they function in the repair of DNA
mismatches [27]. However, we found no significant relation-
ship between MMR protein expression and survival.
Recent reports on ALDH expression in malignancies fo-
cused on a small proportion of the cancer cell population
(approximately 1% of the total tumor volume) which is char-
acterized by a higher tumorigenic potential. These so-called
‘tumor-initiating cells’ have been under investigation in the
last decade and a study on these ALDH-expressing ‘tumor-
initiating cells’ in PDAC and the prognostic significance of
their presence was recently published [17]. Although IHC
Table 3 Univariate analysis for histological factors in 78 PDAC
patients
Total Median
survival
95% CI p value
(log-rank test)
Protein expression
P53 0.84
negative 31 (46%) 30.1 14.1–46.0
nuclear 36 (54%) 25.8 16.5–25.1
Smad4 0.008
a
negative 34 (44%) 15.8 10.4–21.2
positive 49 (56%) 35.6 22.9–48.4
Axl 0.40
negative 54 (78%) 23.6 15.6–31.5
positive 15 (22%) 29.2 16.8–41.6
ALDH (diffuse staining) 0.12
negative 18 (84%) 15.3 8.1–22.5
positive 54 (16%) 28.6 19.1–38.1
ALDH (high-expression) 0.11
negative 58 (84%) 22.7 16.7–28.7
positive 11 (16%) 43.8 9.0–78.6
MSH2 0.45
negative 4 (5%) 30.4 6.6–54.2
positive 69 (95%) 25.15 16.2–39.7
MSH6 0.73
negative 2 (3%) 35.2 0–86.6
positive 70 (97%) 25.0 17.5–32.6
MLH1 0.98
negative 1 (1%) 17.0 17.0–17.0
positive 72 (99%) 25.7 18.3–33.2
PMS2 0.41
negative 5 (7%) 15.2 3.9–26.6
positive 70 (93%) 27.7 19.2–36.2
a Significant correlation with survival
Table 4 Multivariate analysis including: tumor stage, lymph node
status, lymph node ratio, resection margin, tumor stage and Smad4
expression
Variable Hazard ratio 95% CI p value
Tumor resection
margin
R0 1.00
R1 1.86 1.02–3.41 0.044*
Lymph node ratio N0 1.00
N1 2.36 1.37–4.07 0.002*
Smad4 negative 1.00
positive 2.34 1.30–4.21 0.004*
124 N.A. Ottenhof et al.revealed a large proportion of neoplastic cells exhibiting
ALDH expression, Rasheed et al. [17] focused only on the
cells that showed strong nuclear labeling of ALDH with a 2-
foldorhigherintensityascomparedtothe normalacinarcells.
This resulted in a small percentage of ALDH-high tumors
with significant prognostic potential. When scoring for ex-
pression of ALDH in our cohort, 75% of the tumors were
positive, albeit with variable intensity. There was no relation
betweenALDHexpressionand survivaltime. Whenusing the
stringent scoring requirements as suggested by Rasheed et al.
[17], the percentage of ALDH-high tumors was 16%. Again,
we did not find a correlation between high ALDH expression
tumors and survival time. Because cancer research is focused
on ‘tumor-initiating cells’, it seems advisable to further inves-
tigate IHC staining of ALDH protein as our study demon-
strates that discrepancies remain between the various studies.
IHC for the evaluation of protein expression is a fast and
cheap method with great value in the laboratory. For exam-
ple, IHC of Smad4 accurately mirrors Smad4 expression
[28] and IHC demonstrates p53 defects as nuclear-bound
protein. However, for most proteins there is not a standard
method available for scoring IHC stained tumors and this
makes interpretation and comparison of studies cumber-
some. In the current study, this was illustrated in the ALDH
expression analysis, where the two different scoring meth-
ods resulted in a different percentage of ALDH-positive
tumors. Effort should be put into standardization of IHC
scoring to increase the accuracy of evaluating protein
expression using IHC to obtain valid quantitative data [29].
In conclusion, this study confirmed the prognostic sig-
nificance of LNR and resection margin in PDAC in multi-
variate analysis. These two characteristics, together with
Smad4 expression, had a significant effect on survival time
and should be considered when determining patient specific
prognosis. The expression patterns of the other proteins
investigated had no significant relation with overall survival
time in the multivariate analysis. Most of them have been
reported to affect survival in other studies published, but
more research has to be performed before a definitive con-
clusion can be drawn concerning the value of these proteins
in determining prognosis.
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